Add BrightSurf on Google Email

Successful development of multifunctional liquid metal nanocomposites for cancer photoimmunotherapy

The research team developed multifunctional nanocomposites that demonstrate excellent tumor-targeting capability through the EPR effect. Irradiation with near-infrared laser light achieved multidimensional therapeutic effects, including complete elimination of transplanted mouse cancers within 5 days.

SourceJapan Advanced Institute of Science and Technology·JournalAdvanced Composites and Hybrid Materials·DateSep 25, 2025
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.

Genetic screening technique could enhance CAR-T therapies for multiple myeloma and other cancers

Researchers identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment for multiple myeloma and other cancers. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma.

SourceMass General Brigham·JournalNature·TypeExperimental study·DateSep 24, 2025

Chinese Medical Journal review highlights neoadjuvant therapy’s promise in advanced colon cancer treatment

Recent clinical trials demonstrate the potential benefits of neoadjuvant chemotherapy and immunotherapy in improving tumor response and surgical success for patients with locally advanced colon cancer. The approach also reduces the risk of recurrence and metastasis, increasing survival outcomes and decreasing cancer-related complications.

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateSep 19, 2025

Stronger together: A new fusion protein boosts cancer immunotherapy

Researchers developed a fusion protein that blocks the 'do not attack' signal and selectively activates tumor-fighting immune cells. The molecule, combining an IL-2 variant with a PD-1 antibody, induces a multifaceted anti-tumoral T cell response in human lung cancer patients.

SourceUniversity of Basel·JournalScience Translational Medicine·DateSep 17, 2025

Lymph nodes found to be key to successful cancer immunotherapy

Research has shown that lymph nodes provide the right environment for stem-like T cells to survive, multiply, and produce killer cells. Preserving lymph nodes could strengthen immune responses and increase the effectiveness of immunotherapy. The study's findings have important implications for cancer therapy.

SourceUniversity of Melbourne·JournalNature Immunology·TypeExperimental study·DateSep 16, 2025
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.

Researchers develop proximity labeling based antigen amplification technology

The researchers developed a novel cell-surface protein engineering strategy called PATCH, which applies proximity labeling to immunomodulation for the first time. This approach directly amplifies targeting signals on the tumor cell surface, identifying cells that need to be attacked by the immune system.

SourceChinese Academy of Sciences Headquarters·JournalNature·DateSep 15, 2025

Lung cancer rewires immune cells in the bone marrow to weaken body’s defenses

Researchers found that lung tumors reshape immune cells in the bone marrow before they reach the cancer, altering their function and leading to a stronger anti-cancer response. The study identified NRF2 as a key protein involved in this process and proposed blocking it as a potential strategy to enhance immunotherapy.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNature·TypeExperimental study·DateSep 10, 2025

Repurposing a diabetes medication to prime CAR T cancer targets

UCSF researchers develop a new strategy to prime CAR T cell therapy by combining it with diabetes drugs, increasing the efficacy of NECTIN4-CAR T cells in treating urothelial carcinoma. The study shows that using thiazolidinediones enhances NECTIN4 expression, making tumor cells more susceptible to the treatment.

SourceUniversity of California San Francisco Medical Center·JournalNature Communications·TypeExperimental study·DateSep 10, 2025

Breakthrough cancer therapy moves to phase 2 trials

DZ-002 is an innovative cancer treatment developed through a collaborative effort among Georgia State University, Emory University and Cedars-Sinai Medical Center. The technology harnesses targeted radiation to destroy tumors with precision, offering hope for improved patient outcomes.

SourceGeorgia State University·DateSep 9, 2025
Garmin GPSMAP 67i with inReach

Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.

MD Anderson research highlights for September 5, 2025

Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.

SourceUniversity of Texas M. D. Anderson Cancer Center·DateSep 5, 2025

Targeted cell removal offers treatment hope

A team of scientists has developed a protein-based therapeutic tool called Crunch to target and remove specific living cells, such as cancer cells or overactive immune cells. The new system uses the body's natural waste removal system to clear out unwanted cells, offering hope for improved treatments.

SourceInstitute for Integrated Cell-Material Sciences, Kyoto University·JournalNature Biomedical Engineering·DateSep 3, 2025
Nikon Monarch 5 8x42 Binoculars

Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.

Plant-based nutrient improves immune cells’ ability to fight cancer

A study published in Cell Reports Medicine found that zeaxanthin, a plant-derived carotenoid, strengthens the activity of immune cells that kill tumor cells. The findings suggest that zeaxanthin could complement and strengthen advanced cancer treatments like immunotherapy.

SourceUniversity of Chicago Medical Center·JournalCell Reports Medicine·TypeExperimental study·DateSep 2, 2025

A stunning first look at the viruses inside us

Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.

SourceLa Jolla Institute for Immunology·JournalScience Advances·TypeExperimental study·DateAug 27, 2025

New method probes cancer cell messengers that weaken immune system

Researchers at Purdue University have developed a new method to study biochemical processes that impair the immune system's ability to recognize and kill cancer cells. The method involves tracking RNA-binding proteins and extracellular vesicles, which can compromise immunotherapy.

SourcePurdue University·JournalJournal of the American Chemical Society·DateAug 25, 2025

New research points to protecting blood during radiation therapy

Researchers at the University of Navarra have developed FLIP-HEDOS, a model that simulates how much radiation blood absorbs during cancer treatment. The study highlights the importance of protecting blood from radiation, which can impair immune function and lead to hematologic toxicity.

SourceUniversidad de Navarra·TypeExperimental study·DateAug 21, 2025
Aranet4 Home CO2 Monitor

Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.

Study advances understanding of rare type of lung cancer

A recent study published in Nature Communications provides a comprehensive characterization of Large Cell Neuroendocrine Carcinoma (LCNEC), a rare and aggressive type of lung cancer. The research team analyzed data from 590 patients and found that LCNEC shares features with other types of lung cancer, yet has distinct aspects. They ide...

SourceUniversity of Oklahoma·JournalNature Communications·TypeData/statistical analysis·DateAug 20, 2025

Cancer drug eliminates aggressive cancers in clinical trial

In a phase 1 clinical trial, the engineered antibody improved a class of drugs that had struggled to deliver on its early promise. Six patients experienced systemic tumor reduction, including two complete responses, with minimal side effects.

SourceRockefeller University·JournalCancer Cell·DateAug 14, 2025

Resolving the structural basis of therapeutic antibody function in cancer immunotherapy

A team of researchers has visualized the nanoscale architecture of CD20 receptors and their interactions with anti-CD20 antibodies using a novel super-resolution microscopy technique. The study reveals that structural changes in antibody design translate into different receptor patterns and cellular responses, opening up new pathways f...

SourceLudwig-Maximilians-Universität München·JournalNature Communications·DateAug 11, 2025
Celestron NexStar 8SE Computerized Telescope

Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.

This artificial sweetener could make cancer treatment less effective

Research suggests that consuming high levels of sucralose can make cancer treatment less effective by disrupting the gut microbiome and altering T cell function. However, adding arginine or citrulline supplements to the diet may restore immunotherapy effectiveness in patients with melanoma and non-small cell lung cancer.

SourceUniversity of Pittsburgh·JournalCancer Discovery·DateJul 31, 2025
AmScope B120C-5M Compound Microscope

AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.

BATMAN brings TCR therapy out of the shadows

Researchers developed a new AI model named BATMAN to improve T cell receptor therapy accuracy. The AI uses a vast database of over 22,000 TCR-peptide interactions to predict peptide binding and identify potential cancer treatments.

SourceCold Spring Harbor Laboratory·JournalCell Systems·DateJul 25, 2025
Sony Alpha a7 IV (Body Only)

Sony Alpha a7 IV (Body Only) delivers reliable low-light performance and rugged build for astrophotography, lab documentation, and field expeditions.

Shedding light on why immunotherapy sometimes fails

Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.

SourceChiba University·JournalInternational Journal of Pharmaceutics·TypeExperimental study·DateJul 24, 2025

Surprising finding could pave way for universal cancer vaccine

Researchers have discovered an experimental mRNA vaccine that can boost tumor-fighting effects of immunotherapy, sparking a new approach to battling many types of treatment-resistant tumors. The study found that pairing the test vaccine with common anticancer drugs triggered a strong antitumor response.

SourceUniversity of Florida·JournalNature Biomedical Engineering·TypeExperimental study·DateJul 18, 2025

Giving T cells a break: controlled physical barrier created to boost cancer immunotherapy

Researchers developed a biomimetic physical barrier that temporarily blocks T cell-tumor cell interactions, delaying exhaustion and enabling a stronger immune response. The breakthrough strategy can potentially be combined with other immunotherapeutic approaches to enhance treatment efficacy.

SourceChinese Academy of Sciences Headquarters·JournalProceedings of the National Academy of Sciences·DateJul 16, 2025
Apple MacBook Pro 14-inch (M4 Pro)

Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.

Good prognosis for men with prostate cancer treated according to guidelines

A new study from Uppsala University found that most men with prostate cancer who receive recommended treatment have a good prognosis, with a lower risk of dying from prostate cancer than other causes. The study's findings highlight the importance of assessing a patient's life expectancy in choosing an appropriate treatment strategy.

SourceUppsala University·JournalJournal of the National Comprehensive Cancer Network·TypeObservational study·DateJul 14, 2025

Fighting leukemia by breaking a hidden cell loop

Researchers developed a novel immunotherapy that disrupts the IL-33/IL1RL1 signaling loop to boost immune function and improve survival in leukemia patients. The treatment targeted leukemia stem cells, reducing relapse rates and improving survival without major side effects.

SourceMedical University of South Carolina·JournalNature Communications·TypeExperimental study·DateJul 14, 2025
DJI Air 3 (RC-N2)

DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.

Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later

A Phase II study found that 87% of patients with stage III melanoma remained alive and disease-free four years after treatment with nivolumab and relatlimab. Researchers identified unique biomarkers associated with better outcomes, including high TIGIT levels and low B7-H3 levels.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalJournal of Clinical Oncology·DateJul 10, 2025

Longitudinal study sets new survival benchmark for patients with advanced biliary tract cancer

A new study published in the Journal of Hepatology shows that durvalumab plus GemCis significantly improves overall survival for patients with advanced biliary tract cancer. The three-year follow-up analysis found that over twice as many participants treated with durvalumab plus GemCis remained alive compared to those treated with a pl...

SourceElsevier·JournalJournal of Hepatology·TypeRandomized controlled/clinical trial·DateJul 10, 2025

Gut microbes key to understanding how exercise boosts cancer immunity

A new study from the University of Pittsburgh shows exercise improves cancer outcomes and enhances response to immunotherapy in mice by reshaping the gut microbiome. The research found that a specific compound called formate, produced by gut bacteria in exercised mice, was associated with better outcomes in patients with melanoma.

SourceUniversity of Pittsburgh·JournalCell·DateJul 9, 2025

A new cell therapy for leukaemia shows high efficacy and safety in the laboratory

A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.

SourceJosep Carreras Leukaemia Research Institute·JournalJournal of Hematology & Oncology·TypeExperimental study·DateJul 7, 2025
Rigol DP832 Triple-Output Bench Power Supply

Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.

‘Leukemia-on-a-chip’ could transform CAR T blood cancer treatments

Scientists have developed a miniature device that mimics human bone marrow and immune environment, enabling predictive testing of cancer immunotherapy success in patients. The device recreates three regions of bone marrow where leukemia develops and retains the complex immune environment of the tissue.

SourceUniversity of Pennsylvania·JournalNature Biomedical Engineering·TypeExperimental study·DateJul 1, 2025

Cancer: «forgotten» cells go on the offensive

Scientists have discovered that CD4 T cells can target tumour cells with high efficiency, expanding the pool of patients who could benefit from this therapy. A clinical trial is currently preparing to test this approach in adults and children with various types of cancer.

SourceUniversité de Genève·JournalScience Advances·TypeNews article·DateJun 30, 2025

Prognostic factors for non-small cell lung cancer after neoadjuvant therapy and surgery: a retrospective observational study

This study identifies pre-neadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) as significant predictors of postoperative recurrence-free survival in non-small cell lung cancer (NSCLC) patients after neoadjuvant therapy. Smoking history is also a predictor of recurrence in LUSC patients.

SourceNational Center for Respiratory Medicine·JournalJournal of Thoracic Disease·TypeObservational study·DateJun 28, 2025

Cancer immunotherapy shows promise for transplant patients

A new study reveals that cancer-fighting immunotherapy drugs may offer benefits to organ transplant recipients with advanced cancer when carefully managed. The study found that about one in three patients responded positively to treatment within a year, with improved survival outcomes comparable to the general population.

SourceFlinders University·JournalJAMA Oncology·TypeSystematic review·DateJun 24, 2025
Apple Watch Series 11 (GPS, 46mm)

Apple Watch Series 11 (GPS, 46mm) tracks health metrics and safety alerts during long observing sessions, fieldwork, and remote expeditions.

Official BRACELET-1 trial results indicate that adding the oncolytic virus immunotherapy pelareorep to paclitaxel chemotherapy warrants further investigation in HR+ HER2- metastatic breast cancer

The BRACELET-1 trial demonstrated a 20% objective response rate and 12.1-month progression-free survival for patients with unresectable HR+ HER2- tumors, suggesting that adding pelareorep to paclitaxel chemotherapy warrants further investigation in metastatic breast cancer.

SourcePrECOG, LLC·JournalClinical Cancer Research·TypeRandomized controlled/clinical trial·DateJun 24, 2025

MD Anderson Research Highlights for June 11, 2025

Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.

SourceUniversity of Texas M. D. Anderson Cancer Center·DateJun 11, 2025

Scientists design a new tumor-targeting system for cancer fighting cells

Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.

SourceNagoya University·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateJun 10, 2025
Sky-Watcher EQ6-R Pro Equatorial Mount

Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.

Sudy shows that existing drug class may help patients with skin cancer that resists standard treatments

Researchers at NYU Langone Health discovered that a specific biological pathway explains why many patients with deadly melanoma do not respond to latest cancer treatments. The study found therapeutic targets that could limit melanoma growth in patients with NF1 mutations, suggesting a novel approach for treatment.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalCancer Research·TypeExperimental study·DateJun 10, 2025

MET mutation and cancer immunity

A recent study found that MET mutations are associated with enhanced tumor immunogenicity, increased immune cell infiltration, and improved response rates to immune checkpoint blockade. Certain single base substitutions identified as robust predictive biomarkers for survival in pan-cancer immunotherapy.

SourceCompuscript Ltd·JournalGenes & Diseases·DateJun 5, 2025

Inherited genetic trait predicts resistance to immunotherapy for deadly skin cancer

Researchers found a specific genetic mutation, MT haplogroup T, in patients who did not respond to immune checkpoint inhibitors. The study showed that these patients had more underdeveloped T cells and increased resilience to reactive oxygen species, stunting their attack on cancer cells.

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalNature Medicine·TypeExperimental study·DateJun 5, 2025
Kestrel 3000 Pocket Weather Meter

Kestrel 3000 Pocket Weather Meter measures wind, temperature, and humidity in real time for site assessments, aviation checks, and safety briefings.

Study shows loss of Y in blood cells hinders immune response to cancer

Researchers identified a link between the loss of Y chromosome in white blood cells and reduced ability to kill cancer cells. This finding may explain why men with loss of Y have higher cancer risks and poorer outcomes. The study provides insights into how this genetic change affects immune system function.

SourceUniversity of Arizona Health Sciences·JournalNature·DateJun 4, 2025

Immunotherapy before surgery improves lung cancer survival in global clinical trial led by Irish cancer specialist

A global clinical trial led by Irish cancer specialist Prof. Patrick Forde shows that immunotherapy with chemotherapy before lung cancer surgery reduces the risk of cancer returning and improves long-term survival. The study found that patients who received immunotherapy plus chemotherapy had improved outcomes compared to those who rec...

SourceTrinity College Dublin·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJun 2, 2025

Immunotherapy boosts chemotherapy in combating stage 3 colon cancer

A new study found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer resulted in a 50% reduction in cancer recurrence and death compared to chemotherapy alone. The treatment combination showed significant benefits for patients with deficient DNA mismatch repair genetic makeup.

SourceMayo Clinic·DateJun 1, 2025
Fluke 87V Industrial Digital Multimeter

Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.

Dual-target CAR T cell therapy slows growth of aggressive brain cancer

A phase I clinical trial demonstrates that dual-target CAR T cell therapy can reduce tumor size in nearly two-thirds of patients with recurrent glioblastoma, a notoriously aggressive brain cancer. The therapy also shows signs of long-term immune system activation and potential for extended tumor stability.

SourceUniversity of Pennsylvania School of Medicine·JournalNature Medicine·DateJun 1, 2025

Adding immune checkpoint inhibitor to standard chemotherapy regimen improves outcomes in stage 3 colon cancer, study finds

A phase 3 trial of patients with surgically resected stage 3 dMMR colon cancer found that adding an immune checkpoint inhibitor (atezolizumab) to standard chemotherapy improved disease-free survival by 50% compared to chemotherapy alone. The study results provide new evidence for a treatment approach in this high-risk patient population.

SourceDana-Farber Cancer Institute·DateJun 1, 2025